KPTI has been the subject of several other research reports. Cantor Fitzgerald set a $18.00 target price on Karyopharm Therapeutics and gave the stock a buy rating in a research report on Thursday, October 12th. Royal Bank Of Canada started coverage on Karyopharm Therapeutics in a research report on Thursday, September 14th. They issued an outperform rating and a $14.00 target price for the company. Zacks Investment Research lowered Karyopharm Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 7th. ValuEngine lowered Karyopharm Therapeutics from a hold rating to a sell rating in a research report on Thursday, August 31st. Finally, Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics and gave the stock a buy rating in a research report on Tuesday, August 8th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has a consensus rating of Buy and an average price target of $17.33.
Karyopharm Therapeutics (NASDAQ:KPTI) traded up $0.08 on Wednesday, reaching $11.47. The company’s stock had a trading volume of 89,365 shares, compared to its average volume of 241,329. Karyopharm Therapeutics has a fifty-two week low of $7.48 and a fifty-two week high of $14.63.
ILLEGAL ACTIVITY NOTICE: This article was first published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://sportsperspectives.com/2017/11/18/begins-coverage-on-karyopharm-therapeutics-inc-kpti.html.
In related news, SVP Christopher Brett Primiano sold 4,958 shares of the company’s stock in a transaction that occurred on Tuesday, November 7th. The stock was sold at an average price of $11.25, for a total value of $55,777.50. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Mansoor Raza Mirza sold 2,882 shares of the company’s stock in a transaction that occurred on Friday, September 15th. The stock was sold at an average price of $11.00, for a total value of $31,702.00. Following the completion of the sale, the director now owns 2,882 shares in the company, valued at approximately $31,702. The disclosure for this sale can be found here. Insiders sold a total of 15,653 shares of company stock worth $174,728 in the last 90 days. 14.71% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the stock. Voya Investment Management LLC grew its stake in shares of Karyopharm Therapeutics by 42.1% in the 2nd quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock worth $136,000 after buying an additional 4,444 shares during the last quarter. Tudor Investment Corp ET AL purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $136,000. Trexquant Investment LP purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $202,000. American International Group Inc. grew its stake in shares of Karyopharm Therapeutics by 20.9% in the 1st quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after buying an additional 2,836 shares during the last quarter. Finally, State of Wisconsin Investment Board purchased a new stake in shares of Karyopharm Therapeutics in the 2nd quarter worth approximately $235,000. Institutional investors own 59.23% of the company’s stock.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.
Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.